News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca AB Strikes New Deals Worth $140 Million With Hutchison China MediTech (Chi-Med) and Astellas Pharma US After R&D Setbacks



12/21/2011 7:53:45 AM

AstraZeneca PLC Wednesday said it has entered research deals with two Asian drug companies, just one day after suffering setbacks for two important pipeline products. The London-based pharmaceuticals group entered a global deal to co-develop and sell a targeted cancer therapy from Hutchison China MediTech Ltd. and also bought options on a potential new class of diabetes pills from Japan-based Astellas Pharma Inc. The collaboration with China MediTech is a global licensing, co-development and commercialization agreement for a compound named Volitinib--an inhibitor of the c-Met receptor tyrosine kinase for treating cancer, discovered and developed in China by China MediTech and which is about to enter Phase I testing. AstraZeneca will pay the Hong Kong-based company $20 million upfront and up to $120 million if the cancer drug is developed successfully, plus possible significant future commercial sale milestones and up to double-digit percentage royalties on net sales.

Read at Market Watch
Read at Guardian
Read at Reuters
Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES